StockNews.com initiated coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report report published on Monday morning. The firm issued a sell rating on the biotechnology company's stock.
Cellectis Price Performance
CLLS stock traded up $0.07 during mid-day trading on Monday, reaching $1.93. The company's stock had a trading volume of 21,473 shares, compared to its average volume of 46,597. The stock has a market cap of $107.28 million, a PE ratio of -1.49 and a beta of 3.09. The company's 50 day moving average is $2.15 and its two-hundred day moving average is $2.31. Cellectis has a fifty-two week low of $0.96 and a fifty-two week high of $3.77. The company has a current ratio of 1.92, a quick ratio of 1.92 and a debt-to-equity ratio of 0.39.
Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.33) by $0.05. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. The company had revenue of $9.50 million for the quarter, compared to analyst estimates of $6.00 million. Equities research analysts expect that Cellectis will post -0.54 EPS for the current year.
Institutional Investors Weigh In On Cellectis
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its position in Cellectis by 6.2% in the first quarter. Principal Financial Group Inc. now owns 424,533 shares of the biotechnology company's stock valued at $1,125,000 after buying an additional 24,906 shares during the last quarter. Baillie Gifford & Co. boosted its position in shares of Cellectis by 1.3% during the 1st quarter. Baillie Gifford & Co. now owns 827,248 shares of the biotechnology company's stock worth $2,192,000 after purchasing an additional 10,605 shares during the period. XTX Topco Ltd purchased a new stake in Cellectis in the second quarter valued at approximately $29,000. Long Focus Capital Management LLC lifted its stake in Cellectis by 2.9% during the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. Finally, First Affirmative Financial Network purchased a new position in shares of Cellectis during the third quarter worth $45,000. Hedge funds and other institutional investors own 63.90% of the company's stock.
Cellectis Company Profile
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
